Pure Extracts and Psyence Form Joint Venture Corporation Pure Psyence

Article

Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.

Pure Extracts, a plant-based extraction company, and Psyence Group, a biotechnology company specializing in natural psychedelics, announced the formation of a joint venture company on Sept. 28, 2021. The new company, Pure Psyence, will develop nature-derived psilocybin extracts and advanced psilocybin formulations.

Pure Extracts is known for its full spectrum oil extracts and has experience working with cannabis, hemp, functional mushrooms, and psychoactive mushrooms. Their new partner, Psyence, operates one of the first federally-licensed commercial psilocybin cultivation and production facilities in the world.

Pure Psyence will look to develop long-term mental health treatments in the form of psilocybin products. It will leverage Psyence’s supply of psilocybin mushrooms and Pure Extract’s extraction technologies to produce medicinal mushroom extracts and formulations on a commercial pharmaceutical scale.

“Pure Psyence sits at the intersection of evidence-based science and nature,” said Ben Nikolaevsky, CEO, Pure Extracts, in a company press release. “The researchers, scientists, and physicians at Pure Psyence will now be uniquely positioned to bring psilocybin whole mushroom in measurable pharmaceutical dosages to market; a first.”

Source: Pure Extracts

Recent Videos
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
© 2024 MJH Life Sciences

All rights reserved.